POLISH PSYCHIATRIC ASSOCIATION
BOARD INFORMATION

Position of the Polish Psychiatric Association regarding the description of indications for reimbursement of Latuda and Rxulti

1. According to the Summary of Product Characteristics, the drug Latuda (lurasidone) is indicated for use in the treatment of schizophrenia in adult patients and adolescents aged 13 years and older.
2. According to the Summary of Product Characteristics, the drug Rxulti (brexpiprazole) is indicated for use in the treatment of schizophrenia in adult patients.
3. According to the Notice of the Minister of Health on the reimbursement of medicines, foodstuffs intended for particular nutritional uses and medical devices, Latuda (lurasidone) is available free of charge to patients aged 13 and older, while Rxulti (brexpiprazole) is available to adult patients diagnosed with schizophrenia after failure or in the case of contraindications to treatment with other second-generation antipsychotic drugs.
4. In the opinion of the Board of the Polish Psychiatric Association, this means that in order to issue a reimbursed prescription for the product Latuda (lurasidone) or Rxulti (brexpiprazole), in accordance with the decision of the Minister of Health the following is required:
   a) failure of at least one second-generation antipsychotic drug, or
   b) the presence of contraindications to at least one of the second-generation antipsychotic drugs, provided that there are no contraindications to the use of Latuda (lurasidone) or Rxulti (brexpiprazole).
5. The medications may be used in both mono – and polytherapy.
6. The failure of at least one second-generation antipsychotic drug or the presence of contraindications to at least one of the most commonly used second-generation antipsychotics should be confirmed by an appropriate entry in the patient's medical documentation.
7. In the event of a review of the validity of the reimbursement, the patient's medical documentation confirming the fulfillment of the criteria specified in the Notice of the Minister of Health should be made available to the auditors, provided they have the required authorizations.

Dr Michał Mielimąka
Secretary General of the Executive Board
Polish Psychiatric Association

Prof. Dominika Dudek
President of the Executive Board
Polish Psychiatric Association

Warsaw, 14 June 2024

Position of the Polish Psychiatric Association regarding the description of indications for reimbursement of Brintellix

1. According to the current scope of reimbursement indications, the drug Brintellix (vortioxetine) may be used with reimbursement for the treatment of major depressive episodes in adults who have not achieved improvement in the treatment of the current episode despite the use of a drug from the group of selective serotonin reuptake inhibitors or from the group of serotonin norepinephrine reuptake inhibitors.
2. In the opinion of the Board of the Polish Psychiatric Association, on the basis of current guidelines and recommendations as well as scientific knowledge, appropriate clinical practice is to consider the efficacy (and tolerability) of drugs used in the treatment of previous depressive episodes when selecting a drug for the treatment of subsequent depressive episodes for a given patient.

The clinically recommended approach is to use a medication that has been effective and well-tolerated in previous episodes for subsequent episodes, always considering the current mental state of the patient and analyzing the factors and circumstances that may contraindicate the use of a specific drug at the time of prescribing it (e.g., comorbid conditions, pregnancy).

Therefore, in the absence of additional circumstances for using vortioxetine (Brintellix), it is advisable to start the treatment of the subsequent episode with this medication. It would be an error to begin treatment with a drug that was not tolerated or was ineffective in a previous episode (in this case, an SSRI or SNRI). We recommend removing the term "current episode" from the reimbursement indications in the future.

Dr Michał Mielimąka
Secretary General of the Executive Board
Polish Psychiatric Association

Prof. Dominika Dudek
President of the Executive Board
Polish Psychiatric Association

Warsaw, 14 June 2024